EHA 2019
Learnings in B-cell malignancies for clinical practice: from real-world evidence to patient-centric disease management

As valuable data is collected in the clinical trial setting regarding the treatment of B-cell malignancies, implementing these findings into practice and optimizing patient care remain ongoing considerations. What is more, this newly gained data provide insights into the complex process of selecting patients for Chimeric Antigen Receptor (CAR) T-cell therapy.

VJHemOnc interviewed the presenting experts from the Kite Satellite Symposia ‘Beyond clinical trials in B-cell malignancies: what real-world experience tells us’ and ‘A patient-centric approach to CAR-T therapy: from treatment selection to patient management’ hosted during the European Hematology Association (EHA) 24th Congress in Amsterdam, The Netherlands. These sessions included discussion on licensed products, and were organized and fully funded by Kite, a Gilead Company.

Beyond clinical trials in
B-cell malignancies: what real-world experience tells us

Featured speakers:
Loic Ysebaert, Toulouse, France
John New, Manchester, UK
Yi Lin, Rochester, MN
Eoin McGrath, Barcelona, Spain

Satellite Symposium I
A patient-centric approach to CAR-T therapy: from treatment selection to patient management

Featured speakers:
Marie José Kersten, Amsterdam, The Netherlands
Rose Ellard, London, UK

Satellite Symposium II

Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel must be administered at a qualified clinical setting.

Idelalisib is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Idelalisib is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Gilead at safety_FC@gilead.com or +44 (0) 1223 897500.

YESCARTA® (axicabtagene ciloleucel), Kite and the Kite logo are registered trademarks of Kite Pharma Inc © 2019 Kite Pharma, Inc.
ZYDELIG® (idelalisib) is a registered trademark, Gilead and the Gilead logo are registered trademarks of Gilead Sciences Inc © 2019 Gilead Sciences, Inc.